EMA更新teclistamab（Tecvayli）的EPAR：该药用于复发或难治性多发性骨髓瘤成人患者，2022年8月23日获欧盟条件性上市许可，2026年8月20日因公司提交额外数据转为标准上市许可。
关注理由：该EPAR第11版记录teclistamab由条件性上市许可转为标准许可这一监管证据升级，并汇总其单药及联合daratumumab研究的疗效与安全性数据，便于跟踪多发性骨髓瘤后续监管动作。
EMA通报Merck Sharp & Dohme B.V.因商业原因永久停市止吐药Emend（aprepitant，80 mg与125 mg规格），欧盟/EEA短缺持续，预计2028年5月前在所有国家停市，停市与产品质量缺陷或安全问题无关。
关注理由：该通告确认aprepitant停市源于商业原因而非质量或安全问题，6月龄及以上儿童所需口服混悬剂型无替代品，是化疗支持用药供应需持续跟踪的关键缺口。
原文摘录：This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory).
关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
原文摘录：BACKGROUND: Prior analyses of PALLAS (NCT02513394), a phase III trial that randomized patients with stage II-III hormone receptor-positive breast cancer to receive adjuvant palbociclib plus endocrine therapy (ET) or ET alone, did not show benefit of the c … gov, NCT02513394
关注理由：这条肿瘤学内容涉及随机对照研究，建议同时核对纳入人群、主要终点与报告结果。
原文摘录：BACKGROUND: Text message reminders (TMRs) and patient navigation (PN) increase bowel cancer screening uptake. To date, no studies have directly compared these interventions with one another. … TRIAL REGISTRATION: ISRCTN17245519
关注理由：关注肿瘤学时，这项随机对照研究可提供直接比较的证据，主要终点和研究局限需要一起阅读。
原文摘录：BACKGROUND: Fatigue is a common symptom in cancer patients associated with impaired quality of life (QoL). Little is known about long-term fatigue trajectories in prostate cancer (PCa) patients. … PCa patients with elevated pre-radiotherapy fatigue levels and diabetes may require closer monitoring in risk-stratified aftercare programmes
关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
原文摘录：Ibrance - withdrawal of application for variation to marketing authorisation Application withdrawn The application for a change to this medicine's authorisation has been withdrawn palbociclib Post-authorisation Human Overview Pfizer Europe MA EEIG withdre … News on Ibrance Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026 16/10/2026 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected) 21/09/2016 New treatment for breast cancer 16/09/2016 More information on Ibrance Ibrance This page was last updated on 28/10/2026
关注理由：这篇肿瘤学内容涉及临床试验，适合了解研究正在回答什么问题，试验阶段和主要终点需以原文为准。
Merck与Moderna公布intismeran autogene联合Keytruda治疗黑色素瘤术后患者的III期中期结果：中位随访两年，联合组复发或死亡风险较Keytruda单药降低42%，两年未复发率为82.2%对70%，主要终点无复发生存期达到。
关注理由：该评论将泄露后公布的III期中期数据与II期结果及Keytruda单药两年基线对照，指出总生存期尚未成熟、膀胱癌与肾细胞癌数据未读出，有助于把疗效信息与资本市场波动分开看待。
原文摘录：Image credit: © Chinnapong | stock.adobe.com EMA recommends authorisation of Rasonque for metastatic pancreatic cancer 15 October 2026 Phased review fast tracks assessment of medicine addressing unmet medical need News Human Innovation Medicines EMA’s hum … eu All other enquiries Please submit your request via the online form Follow us on Bluesky Related medicine information Rasonque
关注理由：这条肿瘤学内容涉及相关临床或研究问题，建议查看原文中的方法与适用范围。
原文摘录：AIMS: Histologic grading of the primary tumor (PT) is an established prognostic factor in lung adenocarcinoma; however, the clinical relevance of histologic patterns in metastatic lymph nodes (MLNs) remains unclear. … These findings suggest that MLN morphology may provide complementary pathological information regarding patterns of locoregional recurrence after surgical resection
关注理由：关于肿瘤学的这条内容有明确出处，主要发现和适用人群可在原文中继续核查。